<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is the leading cause of <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> in patients starting renal replacement therapy and affects approximately 40% of type 1 and type 2 diabetic patients </plain></SENT>
<SENT sid="1" pm="."><plain>It increases the risk of <z:hpo ids='HP_0011420'>death</z:hpo>, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE) in the absence of other <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is categorized into stages: <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (UAE &gt;20 microg/min and &lt; or =199 microg/min) and macroalbuminuria (UAE &gt; or =200 microg/min) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo>, <z:e sem="disease" ids="C0497247,C0020538" disease_type="Disease or Syndrome;Finding" abbrv="">increased blood pressure</z:e> levels, and genetic predisposition are the main risk factors for the development of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Elevated serum <z:chebi fb="23" ids="18059">lipids</z:chebi>, smoking habits, and the amount and origin of dietary protein also seem to play a role as risk factors </plain></SENT>
<SENT sid="5" pm="."><plain>Screening for <z:mp ids='MP_0002959'>microalbuminuria</z:mp> should be performed yearly, starting 5 years after diagnosis in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> or earlier in the presence of puberty or poor metabolic control </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, screening should be performed at diagnosis and yearly thereafter </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with micro- and macroalbuminuria should undergo an evaluation regarding the presence of comorbid associations, especially <z:hpo ids='HP_0000488'>retinopathy</z:hpo> and macrovascular disease </plain></SENT>
<SENT sid="8" pm="."><plain>Achieving the best metabolic control (A1c &lt;7%), treating <z:hpo ids='HP_0000822'>hypertension</z:hpo> (&lt;130/80 mmHg or &lt;125/75 mmHg if <z:hpo ids='HP_0000093'>proteinuria</z:hpo> &gt;1.0 g/24 h and <z:hpo ids='HP_0003259'>increased serum creatinine</z:hpo>), using drugs with blockade effect on the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system, and treating <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> (<z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> &lt;100 mg/dl) are effective strategies for preventing the development of <z:mp ids='MP_0002959'>microalbuminuria</z:mp>, in delaying the progression to more advanced stages of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and in reducing cardiovascular mortality in patients with type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>